Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 11th Preview)
-
FDA approvals
The FDA approved Moderna’s seasonal influenza mRNA vaccine (mRNA-1010, mFLUSIVA) for adults, marking the first FDA clearance for an mRNA flu shot in the U.S. The approval followed a unanimous VRBPAC vote based on Phase 3 results in adults aged 50–64. In head-to-head data, Moderna reported its vaccine was 26.6% more effective than a standard flu vaccine, with comparable serious adverse events. The company also flagged higher reactogenicity, driven by more frequent mild side effects such as injection-site pain. The approval extends the clinical footprint of mRNA platforms beyond COVID-19 and reinforces expectations that mRNA incumbents can win competitive differentiation even in seasonal settings. Moderna said it is also managing post-market study commitments required by the FDA. —
-
Company earnings & platform expansion
Alamar Biosciences reported a sharp revenue rebound in its first full quarter as a public company, alongside an expansion of a large-scale plasma proteomics collaboration tied to Alzheimer’s. In Q2 2026, Alamar’s revenue rose 81% year over year to $29.4 million, driven by nearly doubled product revenue and growth in instruments and consumables. The company forecast 2026 revenue of $116 million to $120 million at midpoint, projecting 59% growth. Separately, Alamar said it expanded its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to analyze an additional 86,000 plasma samples using its NULISAseq Neuro 220 neurology panel, pushing the total analyzed samples to more than 140,000. The expanded dataset is intended to pair multiplex protein profiling with deep clinical phenotyping to capture variation across individuals and populations. —
-
Clinical trial failures in competitive areas (cystic fibrosis)
Sionna Therapeutics ended its cystic fibrosis add-on strategy after a Phase 2 trial failed to show benefit when paired with Vertex’s Trikafta. In the Precision CF study, Sionna’s SION-719 plus Trikafta did not yield a statistically significant placebo-adjusted change in sweat chloride levels compared with Trikafta alone. Sionna also said it will take steps to preserve capital while assessing next steps after the disappointing clinical readout. The failure quickly reshaped investor expectations for Sionna’s ability to challenge Vertex’s CF franchise, and the company’s shares fell sharply in response. Sionna had framed a larger sweat chloride difference as clinically meaningful, but reported the observed separation fell short of its own target. —
-
Clinical trial success driving advancement (rare blood cancer)
Silence Therapeutics announced Phase 2 success for divesiran in polycythemia vera, setting up a move into Phase 3 for the gene-silencing therapy. In the 48-patient trial, Silence said 88% of patients achieved a clinical response on divesiran across dosing intervals of every six or 12 weeks, versus 19% with placebo. Silence characterized the result as meeting the primary endpoint, strengthening the case for continued development of the siRNA candidate. The company positioned the readout as a potential differentiator in a crowded treatment landscape where controlling red blood cell levels is central to reducing thrombotic and bleeding risk. —
-
Dealmaking & expansion (epilepsy)
Jazz Pharmaceuticals agreed to acquire Actio Biosciences in a deal that could total more than $1.3 billion, adding a clinical-stage precision therapy targeting KCNT1-related epilepsy. Under the terms, Actio shareholders will receive $820 million upfront, plus up to $500 million in additional payments tied to milestones. Actio’s lead asset, ABS-1230, is in clinical testing for KCNT1+ epilepsy, a rare genetic epilepsy with no FDA-approved treatments. Jazz said the acquisition supports its neuroscience strategy and complements its existing epilepsy franchise, including Epidiolex. The companies expect to close in the final three months of the year, with Actio spinning out another program concurrently. —
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.